ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

CDC Whistleblower Reveals Widespread Manipulation of Scientific Data and Top-Down Pressure on CDC Sc...

Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel

9 Health Benefits of Cucumbers

Preserving Cognitive Function with Aging

Coenzyme Q10 Benefits Symptoms in Gulf War Veterans: Results of a Randomized Double-Blind Study

Antibiotics in early life may alter immunity long-term

Low vitamin D levels linked to increased risks after noncardiac surgery

How Glutathione Can Save Your Life

New Research Helps Explain Why Elderly Are Prone to Sleep Problems

VIDEO: Relaxation - Ocean Voyager Part I

 
Print Page
Email Article

Study Examines SEROQUEL for the Treatment of Agitation in Elderly Patients with Dementia

  [ 285 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 22, 2004


Study Examines SEROQUEL for the Treatment of Agitation in Elderly Patients with Dementia -- Study Results Suggest SEROQUEL May Reduce Symptoms of Agitation Associated With Dementia in Long-Term Care Patients; Analysis Shows No Evidence of an Increased Risk of Cerebrovascular Adverse Events -- WILMINGTON, Del., July 22 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced data at the 9th International Conference on Alzheimer's Disease and Related Disorders that examined the effectiveness of SEROQUEL(R) (quetiapine fumarate) in the treatment of agitation in elderly patients with dementia. The data suggest SEROQUEL may reduce symptoms of agitation in elderly patients with dementia. The analysis also reported there was no evidence of an increased risk of cerebrovascular adverse events (CVAEs), which have been associated with the use of some other atypical antipsychotics in this population.(1) SEROQUEL is currently approved for the treatment of schizophrenia and for the short-term treatment of acute manic episodes associated with bipolar I disorder. Agitation in Elderly Dementia Patients In this 10-week double blind trial, a total of 333 patients with symptoms of agitation were randomized to receive either SEROQUEL 100mg/day, 200mg/day or placebo. Agitation symptoms were measured using the Positive and Negative Syndrome Scale-Excitement Component (PANSS-EC) measurement scale. In three separate analyses of PANSS-EC data conducted at the end of the study, patients taking 200 mg/day of SEROQUEL reported significantly greater reduction in PANSS-EC scores compared to those taking placebo (p<.05); and in a fourth analysis, the result approached statistical significance (p = 0.065). SEROQUEL 100 mg/day achieved numerically greater reductions in the PANSS-EC compared to that of placebo; however, the difference did not reach statistical significance. SEROQUEL was initiated at 25 mg/day on Day 1 and increased by 25 mg/day to reach a target dose of either 100 mg/day by Day 4 or 200 mg/day by Day 8.(1) The incidence of adverse events (AEs) and serious AEs were similar in each treatment group except for somnolence and sedation which were more common in the SEROQUEL groups. However, somnolence and sedation were rated mild to moderate in most patients. The incidence of falls and postural hypotension were also similar among the treatment groups. No cerebrovascular AEs were reported in either SEROQUEL group in this analysis. "Agitation is a significant issue for patients suffering from this condition and their caregivers. It is an aspect of dementia that is both difficult to manage and emotionally troubling for those who care for patients suffering from dementia," said Pierre Tariot, M.D., Professor of Psychiatry, Medicine and Neurology at the University of Rochester. "These new study results are helpful, informative, and justify further investigation of SEROQUEL for agitation in dementia patients." CVAE analysis AstraZeneca also announced results from an analysis of CVAEs (stroke and transient ischemic attacks) of two 10-week, double-blind placebo-controlled trials. A total of 684 patients (mean age 83 years, 86% with Alzheimer's Disease, 13% with vascular dementia, 1% with other dementia types) were randomized to receive SEROQUEL, haloperidol or placebo. The numbers of patients who experienced CVAEs in this pooled data analysis were one in the SEROQUEL (0.3%) group, one in the haloperidol (0.9%) group, and four in the placebo group (1.9%).(2) "This is an important analysis that examines the incidence of CVAEs in elderly patients with dementia being treated with SEROQUEL," said Kate Zhong, Medical Director, AstraZeneca. "AstraZeneca has a clear commitment to the development of new treatments for mental illness, and is proud of how successful SEROQUEL has been since its launch in 1997." Since its launch, 27.4 million SEROQUEL prescriptions have been written for 6.8 million patients.(3) IMPORTANT SAFETY INFORMATION Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome has been reported with this class of medications, including SEROQUEL. There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL. The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia and weight gain. The physician who elects to use SEROQUEL for extended periods of time should periodically re-evaluate the long-term usefulness of the drug for individual patients. For SEROQUEL full prescribing information, please visit http://www.seroquel.com. ABOUT ASTRAZENECA AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies, with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is an $8.7 billion healthcare business with more than 11,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com. (1) Zhong K, Tariot P, Minkwitz MC, Devine NA, Mintzer J. Quetiapine for the treatment of agitation in the elderly institutionalized patients with dementia: a randomized, double blind trial. International Conference on Alzheimer's Disease and Related Disorders meeting, 2004, Poster # P2-442. (2) Schneider L, Zhong K, Tariot P, Minkwitz MC. Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. International Conference on Alzheimer's Disease and Related Disorders meeting, 2004, Poster # P2-443. (3) Data on File. SOURCE AstraZeneca Web Site: http://www.astrazeneca-us.com http://www.seroquel.com Company News On Call: Company News On-Call: http://www.prnewswire.com/comp/985887.html



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamin B-12

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid

Natural Remedies

Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
"It's Not Easy Being Green" - But It Is Healthy
Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing